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Abstract 
Objective 
To explore ongoing symptoms, unmet needs, psychological wellbeing, self-efficacy and overall health 
status in prostate cancer survivors. Subjects/patients and Methods  
An invitation to participate in a postal questionnaire survey was sent to 546 men, diagnosed with 
prostate cancer 9 – 24 months previously at two UK cancer centres. The study group comprised men 
who had been subject to a range of treatments: surgery, radiotherapy, hormone therapy and active 
surveillance.  The questionnaire included measures of prostate-related quality of life (EPIC-26); 
unmet needs (SCNS SF34); anxiety and depression (HADS), self-efficacy (modified Self-efficacy Scale), 
health status (EQ-5D) and satisfaction with care (questions developed for study). A single reminder 
was sent to non-responders after three weeks. Data were analysed by age, co-morbidities, and 
treatment group. 
Results  
316 men completed questionnaires (64.1% response rate). Overall satisfaction with follow-up care 
was high, but was lower for psychosocial than physical aspects of care.  Urinary, bowel, and sexual 
functioning was reported as a moderate/big problem in the last month for 15.2% (n = 48), 5.1% (n = 
16), and 36.5% (n = 105) men, respectively. The most commonly reported moderate/high unmet 
needs related to changes in sexual feelings/relationships, managing fear of recurrence/uncertainty, 
and concerns about the worries of significant others. It was found that 17% of men (n = 51/307) 
reported potentially moderate to severe levels of anxiety and 10.2% reported moderate to severe 
levels of depression (n = 32/308).  The presence of problematic side-effects was associated with 
higher psychological morbidity, poorer self-efficacy, greater unmet needs, and poorer overall health 
status.  A
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Conclusion 
While some men report relatively few problems following prostate cancer treatment, this study 
highlights important physical and psycho-social issues for a significant minority of prostate cancer 
survivors. Strategies for identifying those men with on-going problems, alongside new interventions 
and models of care, tailored to individual needs, are needed to improve quality of life. Key words: 
Prostate cancer; follow-up care; survivors; Quality of Life; primary care 
 
Introduction 
Prostate cancer is the commonest non-dermatological cancer in men in the Western world.  In 2011 
there were 41,736 new cases in the UK, and over 10,000 deaths [1].  Although it represents the 
second commonest cause of death from cancer, improvements in early detection and treatment 
strategies has resulted in a global improvement in survival statistics, more marked in economically 
developed nations [1] [2]. Treatments for localised disease include radical prostatectomy, external 
beam radiotherapy, and brachytherapy, often with androgen deprivation therapy. Active 
surveillance is offered to men whose disease is considered clinically insignificant for them at the 
time of diagnosis, with regular re-assessment of disease and patient factors to determine if and 
when a need for radical therapy arises; its underlying premise is to avoid or delay. Locally advanced 
disease is typically managed with radiotherapy plus androgen deprivation therapy, with some 
proponents offering surgery as part of multimodal therapy[3], whereas metastatic prostate cancer is 
usually managed by initial androgen deprivation therapy alone [4]. 
Over and above regular PSA monitoring for the detection of recurrence, it is recognised that prostate 
cancer patients can have a wide range of follow-up needs including the management of both 
physical and psycho-social side-effects of diagnosis and treatment [5] [6]. However, a recent survey 
conducted by Prostate Cancer UK reported that over a quarter of men felt that the provision of good 
quality information and support was not adequate for their needs, and almost one-third reported 
follow-up care was not sufficient in terms of addressing the side-effects of treatment [7]. Previous 
studies have also highlighted supportive care needs [8, 9] and shortcomings with existing follow-up 
services [10] in this patient population.  
The increase in demand for follow-up care is placing a significant strain on hospital outpatient clinics.  
To resolve this, it has been suggested that primary care could play a larger role in cancer follow-up 
[11]. NICE currently recommends a move to follow-up outside of the hospital setting for prostate 
cancer patients who are stable at 24 months post-diagnosis [12], although findings from a recent 
audit indicate that specialist MDTs in England currently expect approximately 30% of prostate cancer A
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patients with low-risk disease who receive radical treatment to be followed up for longer than 5 
years, despite the low risk of relapse [13]. This audit report also recommends that the availability of 
personal support services including cancer advisory centres, sexual function and continence advice, 
and psychological counselling should be improved [13]. The American Cancer Society have recently 
published their guidelines advocating that follow up care should be provided in the primary care 
setting soon after hospital treatment finishes [14].    
The survey reported herein was conducted as the first phase of a larger study developing and pilot 
testing a nurse-led psycho-educational intervention delivered to men in primary care (PROSPECTIV) 
[15]. In a sample of UK men with prostate cancer who had completed initial treatment and were 
living with stable disease, we assessed: 1) symptoms experienced and the extent to which men 
found these bothersome; 2) unmet needs; 3) psychological morbidity; 4) self-efficacy; 5) satisfaction 
with care and 6) overall health status, with a view to informing new models of follow-up.  We 
collected this information as a baseline measure of quality of life outcomes against which to 
compare the findings of our future intervention study, and to inform the development of alternative 
models of follow-up. 
 
Subjects/Patients and Methods 
Recruitment 
Men were recruited to the study from two cancer centres in the UK (Oxford University Hospitals NHS 
Trust and Cambridge University Hospitals NHS Foundation Trust). We sought to invite all men 
diagnosed 9-24 months previously, regardless of treatment modality, whose condition was 
considered stable as judged by the most recent prostate specific antigen (PSA) test result. We 
selected nine months post-diagnosis as the time when most radical treatments would have been 
completed.  We used the following criteria as an indication of stable disease: surgical patients - PSA 
≤ 0.2 ng/ml; radiotherapy (brachytherapy or external beam) patients: PSA ≤ 2 ng/ml; hormone 
therapy patients: PSA ≤ 10 ng/ml. Eligible men were identified from clinic databases and clinic 
patient records. 
546 men were sent an invitation to participate, signed by a consultant from their hospital team. The 
invitation included a patient information sheet, a self-completion questionnaire, and a reply paid 
envelope. A single reminder was sent to non-responders after three weeks. 
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Questionnaire 
The questionnaire (Appendix 1), which was designed to assess men’s follow-up care and post-
diagnosis and treatment quality of life, measured: clinical details; satisfaction with follow-up care 
(questions developed for the study); prostate-related quality of life; unmet needs; psychological 
well-being; self-efficacy; co-morbidities; health status; and standard socio-demographic details. 
Wherever possible, existing validated scales were used (see below). 
Prostate-related quality of life 
Prostate related quality of life was measured using the Expanded Prostate Cancer Index Composite -
26 item version (EPIC-26), which is a brief, valid and reliable subjective measure of health quality 
among patients with prostate cancer [16]. The measure comprises 26 items across the following 5 
domains: urinary incontinence; urinary irritation/obstruction; bowel function; sexual and vitality 
functions; hormonal disturbance. As well as measuring functioning in each of the domains, the 
measure also assesses the extent to which functioning is perceived to be a problem by the patient. 
Unmet Needs 
The Supportive Care Needs Survey 34 item version (SCNS- SF34) assesses respondents’ current level 
of need across the following domains: psychological, health system and information, physical and 
daily activity, patient care, and support and sexuality. Need is rated on a 5 point scale ranging from 
no need to high need (1 = no need, 2 = need was satisfied, 3 = low need, 4 = moderate need, 5 = high 
need) [17]. This validated instrument has been previously used in cancer survivorship studies [18]. 
Psychological Wellbeing  
Psychological wellbeing was assessed using the Hospital Anxiety and Depression Scale (HADS) [19]. 
The HADS is a validated and widely used, 14-item screening instrument for assessing levels of 
anxiety and depression in patients. Each item is scored from 0-3. The anxiety and depression sub-
scores are both on scales of 0-21. Scores of 8-10 on either sub-scale indicate possible cases, and 
scores of ≥11 indicate probable cases. The HADS has also previously been used in studies of cancer 
survivors [20].  
Self-Efficacy  
The Self-Efficacy for Managing Chronic Disease Scale [21] was developed  to measure self-efficacy in 
people with chronic conditions and has also been used with cancer patients[22]. Respondents rate 
their confidence to perform six self-management behaviours (1 = ‘not at all confident’ to 10 = ‘totally 
confident’). A mean score is calculated (range 1 to 10) with a high score indicating high self-efficacy. 
Following the method of Foster et al.[22], we added 5 cancer-specific self-management behaviours 
using the same rating scale and calculated a mean score (range 1–10). This new Cancer Survivors Self 
Efficacy Scale of 11 items has been shown to form a strongly homogenous, uni-dimensional scale of A
cc
ep
te
d 
A
rt
ic
le
 
 
 
This article is protected by copyright. All rights reserved. 
self-efficacy (H = 0.54) with excellent reliability (alpha = 0.92)[22]. 
Health Status 
The EQ-5D-5L was used as a measure of health status [23]. A crosswalk algorithm was used to 
convert the 5L EQ5D to the 3L version[24]. Each of the five dimensions in the EQ-5D (mobility, self-
care, activities, pain/discomfort, and anxiety/depression) is scored from 1 (no problem) to 3 
(extreme problem), generating a profile (e.g. 11232) that can be used to calculate a single index 
score (range: 0.04 to 1.000). The EQ-5D also generates a self-rating of health-related quality of life 
scored from 0 to 100 on a visual analogue scale (VAS). 
Satisfaction with Care 
As we were unable to find any suitable, previously validated measures, satisfaction with care was 
measured using 5 questions developed for this study. User representatives were involved in 
developing and pilot testing the questions which asked participants to rate, on a 5-point Likert scale 
ranging from ‘not at all satisfied (score =1)’ to ‘totally satisfied (score=5)’, how well their follow up 
care had addressed any a) physical problems / symptoms b) emotional/psychological problems c)  
relationship problems d) social problems. A final item asked participants to rate their overall 
satisfaction with general support and care, using the same Likert scale.  Items were analysed 
individually. 
Statistical analysis  
Data analysis was undertaken using SPSS software version 22.0. Descriptive statistics were produced, 
using medians and inter-quartile ranges instead of means and standard deviations in cases of heavily 
skewed data. The standardised questionnaires were analysed and missing data handled in 
accordance with their respective guidelines. Associations between the reporting of moderate or 
large problems according to the EPIC questions and other measures included in the questionnaire 
were explored. In addition, sub-group analyses based on age (≤65 years vs 66+), co-morbidities (0 vs 
1 vs >1), and treatment group were carried out. Statistical significance tests were only carried out if 
clinically significant differences were observed. Independent samples t-tests were used to compare 
means, and the non-parametric equivalent was used to compare medians in the case of skewed 
data. Proportions were compared using the chi-square test.  Associations could not be explored 
using multivariate regression analyses due to limitations in the sample size, particularly in terms of 
the low numbers within each treatment group.  
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Results 
Recruitment and sample characteristics 
546 questionnaires were posted and 369 completed questionnaires were returned. Of these, 53 
were excluded because the date of diagnosis given by the respondent on the questionnaire was 
outside our inclusion criteria, leaving a total of 316 responses from a potentially eligible population 
of 493 (response rate = 64.1%). There was no significant difference between respondents and non-
respondents by age, time since diagnosis, and recruitment centre. Sample demographics and clinical 
characteristics are presented in Table 1. The mean age of the sample was 67.8 years (SD = 7.6 years; 
range 46-88 years), most were married (n = 275; 89%), and the overwhelming majority were White 
British (n = 292; 95%). 
At the time of completing the survey, the average time since initial diagnosis was 17.1 months (SD = 
4.5). Just over a third of patients had undergone surgery (n = 115; 37%) or radiotherapy (n = 117; 
37%) as their primary treatment for prostate cancer, with the majority of those undergoing 
radiotherapy also receiving adjuvant hormone therapy (n = 81; 26%). Other primary treatment 
methods included brachytherapy (n = 17; 5%), hormone therapy only (n = 36; 11%), and active 
surveillance (n = 43; 14%). Four patients did not provide their treatment details. Two-thirds of 
respondents (n = 205; 65%) had at least one co-morbidity.  
Current care and satisfaction with care 
The mean time between participants’ last and next outpatient appointment was 6.6 months (SD = 
3.6 months), with just over half either usually or always seeing the same person (n = 191; 61%). 
Around half (n = 171/315; 54%) saw a consultant at their last out-patient appointment, a quarter 
saw a doctor other than a consultant (n = 73/315; 23%), and a fifth saw a nurse (n = 62/315; 20%). 
Respondents reported a mean journey length of 43 minutes (SD = 23 minutes) to their last out-
patient appointment, and a median wait time of 20 minutes (IQR = 10-30 minutes). The mean length 
of their last consultation was 14 minutes (SD = 7 minutes). Very few reported having a regular 
follow-up schedule set-up with their GP (n = 6; 2%), with the majority only interacting with their GP 
to get PSA test results (n = 195; 62%). 
Patients reported high levels of overall satisfaction with the support and care they had received 
(median score = 5, IQR: 4-5). Satisfaction was, however, lower in relation to how well 
emotional/psychological problems (median score=4, IQR: 3-5), relationship (median score = 4, IQR: 
3-5) and social problems (median score = 4, IQR: 3-5) had been addressed, compared to physical 
problems (median score = 5, IQR: 4-5).   A
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Patient-reported symptoms 
Table 2 presents symptoms experienced in the past four weeks as measured by the EPIC-26, broken 
down by primary treatment received. EPIC domain summary scores are also reported. Figure 1 
presents the degree to which men reported urinary, bowel, and sexual functioning and hormone- 
related issues to be a problem to them in the past month.  
One in ten respondents (30/315; 10%) missed out the question relating to overall sexual function 
entirely, with many indicating in the open ended text box provided that they perceived the question 
to be irrelevant to their current situation. Of those that did answer, around three-quarters (n = 
233/285; 82%) reported that their overall sexual function had been poor in the last four weeks. 
Around half (n = 107/233; 46%) of those reporting poor overall sexual function considered this to be 
a moderate or big problem for them over the past month. Of those, less than half (n = 47/107; 44%) 
had discussed this issue at their most recent outpatient appointment, while 16% (n = 17/107) had 
previously been referred to a specialist for this reason. Nearly all were married or cohabiting with a 
partner (n = 105/107; 98.1%), but there was no significant correlation with age. Sexual function was 
a moderate/big problem mostly among those who had hormone therapy (with or without 
radiotherapy) as a primary treatment (n = 99/102; p<0.0001). 
Urinary and bowel functioning was considered a moderate/big problem over the last month by 
15.2% (n = 48/315) and 5.1% (n = 16), respectively. The main symptoms relating to urinary function 
were general incontinence issues such as urinary control and leaking, in addition to the need to 
urinate frequently. Of those who reported their urinary or bowel function was a moderate or big 
problem to them, 31% (n = 15/48) and 38% (n = 6/16) respectively had previously been referred to a 
specialist. The symptoms reported for both urinary and bowel function correlated well with the 
extent to which the patient perceived this issue to be a problem for them. There were no notable 
differences across treatment groups in terms of prevalence of urinary function problems, but bowel 
function problems were most common among those who had undergone radiotherapy in 
combination with hormone treatment. Of those reporting a moderate/big problem with their 
urinary or bowel function, 73% (n = 35/48) and 63% (n = 10/16) respectively had discussed the 
problem at their last outpatient appointment.  
For hot flushes, lack of energy and change in body weight the comparable proportions were 19.1%, 
20% and 13%, whereas for feeling depressed and breast tenderness, the proportions were much 
lower (7% and 2.8% respectively).  
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Health status 
Overall health status, measured using the EQ-5D-5L, was comparable, if not better than population 
norms [25, 26], with an overall mean index score of 0.852 (SD = 0.173) and an overall mean VAS 
score of 79.73 (SD = 16.20). Mean index scores were significantly lower for those reporting 
moderate/big problems with their bowel or urinary function, but those with equivalent sexual 
function problems did not present with significantly lower scores (see Table 4). 
Unmet needs  
Table 3 presents the most commonly reported unmet needs. The most prevalent unmet needs 
related to sexual issues, concerns about significant others, and anxieties around the possibility of 
recurrence. 
On average, those reporting overall urinary and bowel function as a moderate/big problem for them 
had a significantly greater number of unmet needs (urinary: 11.44 vs 4.84; p < 0.001; bowel: 16.44 vs 
5.37; p < 0.001). This was also the case for sexual function (9.27 vs 4.11, p < 0.001).  
Psychological well-being  
The proportion of possible or probable cases of clinical anxiety and depression (anxiety: n = 51/307; 
17%; depression: n = 32/308; 10%) were no higher those reported for the general population [27]. 
The proportions of possible/probable cases of anxiety and depression were significantly larger 
among those reporting moderate or large symptom problems. Of the possible or probable cases of 
clinical anxiety or depression, 12% (n = 6/51) and 16% (n = 5/32) respectively had been referred to 
specialist for this reason. Overall, only 5% (n = 17/315) had been referred to a specialist for anxiety 
or depression problems.  
Those with more than one co-morbidity were significantly more likely to have possible/probable 
clinical levels of anxiety and depression compared to those with no co-morbidities (anxiety: 28.8% vs 
9.4%; p<0.001; depression: 21.9% vs 4.7%; p<0.001). 
Self-efficacy 
Responses on the modified self-efficacy scale were generally high, with a median confidence score of 
at least eight obtained across all activities (where 1 = not at all confident and 10 = totally confident). 
Respondents reported being generally confident with their ability to keep fatigue, physical 
discomfort,  emotional distress or  any other symptoms or health problems from interfering with the 
things they want to do. In relation to cancer specifically, respondents were also generally confident 
they could access information and support, deal with problems the cancer may have caused, and 
contact their doctor with any problems. Those with moderate/large symptom problems reported A
cc
ep
te
d 
A
rt
ic
le
 
 
 
This article is protected by copyright. All rights reserved. 
lower scores on average across all of the self-efficacy questions (some significantly lower), although 
for the most part the reduction was by less than one point on the 10-point scale.  
Discussion 
This study enriches our knowledge of the issues that are important to prostate cancer survivors 
within 2 years of diagnosis in the UK. It both confirms and extends the previous work of Glaser et al. 
[5] and Ream et al. [6] and describes the level of symptoms, unmet need, and psychological well-
being in men with stable disease. Our study also presents new and important information on the 
extent to which men in the UK find ongoing symptoms to be bothersome, levels of satisfaction with 
current follow-up care, and mens confidence to self-manage problems that arise.  
We report significant variation in the types and scale of issues experienced by men. Overall, the 
picture is a fairly encouraging one, with many men experiencing relatively few problems in the post-
treatment phase, and reporting high levels of satisfaction with the follow-up care they have 
received.  However,  whilst these findings may well be a true reflection, the challenges of accurately 
measuring patient satisfaction, and the reluctance of patients to criticise the care they have received 
have been previously noted in the literature [28]. Ongoing symptoms were present in a significant 
proportion of the men in our study, particularly in relation to sexual functioning and, to a lesser 
degree, urinary and bowel functioning. Problems with fatigue, weight gain and hot flushes, often 
associated with hormone therapy, were also reported. For some men, these issues are not 
considered bothersome, and intervention may not be necessary, whereas for others they can have a 
very significant impact on quality of life, potentially affecting relationships and social activities, and 
leading to or contributing to anxiety and depression.  
Many of the problems men are experiencing can potentially be lessened by relatively simple 
interventions, and a recent review concluded that promoting self-management in men with prostate 
cancer is an effective strategy [29]. For example, pelvic floor exercises, bladder retraining, 
monitoring fluid intake and avoiding alcohol and caffeine can positively influence troublesome 
urinary symptoms [12]. In some instances, treatment with drugs will also be indicated. Similarly, 
dietary changes and pelvic floor exercises can have a positive impact on bowel problems. In cases 
where symptoms cannot be improved, properly assessing incontinence and appropriate use of 
continence aids may improve quality of life.  For hot flushes, in addition to the promotion of self-
management strategies  such as cotton clothing and avoiding hot drinks, evidence also supports the 
use of pharmacological interventions [30]. 
For men with sexual dysfunction, patient education and appropriate prescribing of PDE5 inhibitors, 
or where that fails, use of medicated urethral system for erections (MUSE), vacuum pumps or intra-A
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cavernous injections may be helpful for enhancing sexual function [31-33]. However, it is often not 
possible to fully resolve treatment-related sexual dysfunction and, in those cases, it may be 
appropriate to offer the patient (and partner if appropriate) counselling and support to come to 
terms with this, and to find new ways of fulfilling intimacy [32, 34, 35]. It is of note that we found 
men were more likely to discuss urinary/ bowel problems than sexual problems at follow-up 
appointments. It is important that health professionals learn ways to facilitate conversations about 
sexual issues, regardless of the age of the patient.   
Strengths of this study include: assessment of over 300 men who had a range of different prostate 
cancer treatments; participants from two large geographical areas of the UK – Thames Valley and 
the Eastern Counties (Cambridgeshire, Bedfordshire, and Suffolk); and a relatively high response 
rate.  However, although we found that there was no significant difference between respondents 
and non-respondents by age, time since diagnosis, and recruitment centre, volunteer bias cannot be 
excluded. Those with the greatest need may be less or more likely to participate in such a study. It 
may also be that the two areas included in the study are not representative of the wider UK 
population, although our sample is similar in terms of mean age and proportion with university 
degree to that reported in a large study which recruited men with prostate cancer from 66 cancer 
facilities across England [18]. The cross-sectional nature of our study also means we cannot infer 
causality between prostate cancer treatment and the symptoms reported by men. However, 
previous population-based studies have included age-matched controls and have found elevated 
levels of the symptoms described in this paper in men with prostate cancer[36].  Finally, whilst we 
sought to include the most relevant and valid measures available in our questionnaire, it is possible 
that alternative measures may have captured different outcomes of relevance to prostate cancer 
survivors. 
In conclusion, this survey of men in the UK has shed new light on the experiences of prostate cancer 
survivors in the post-treatment phase. Our findings suggest that many men are doing relatively well, 
but with important physical and psycho-social effects occurring in a significant minority. Methods for 
risk stratification and identification of those men with on-going problems [37], alongside new 
interventions and models of care which are tailored to individual needs are needed to improve 
quality of life.  We suggest that primary care practitioners have many of the necessary skills to 
address the issues that we have identified as being of importance to prostate cancer survivors.  If 
methods are developed to stratify which prostate cancer survivors are at low risk of problems, and 
primary care practitioners are provided with some prostate cancer-specific education – particularly 
in relation to psycho-sexual aspects of prostate cancer, we suggest that primary care could be well 
placed to play a greater role in prostate cancer follow-up. An initial assessment by the treating A
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hospital clinician post-treatment could identify which men need further hospital-based care and 
which can be safely and well managed in primary care. Blood tests for the monitoring of PSA levels, 
and regular delivery of hormonal therapy injections, are already overseen in the primary care 
setting. This regular contact in a local, familiar environment may present an ideal opportunity to 
provide more generalised follow-up support to men, and to complement hospital-based care. 
Previous studies have however highlighted that education, adequate resourcing, fool-proof systems 
for surveillance, and easy access back to secondary care when required are key to the success of 
increased primary care involvement in cancer follow-up care[38]. Further research is required to find 
the most effective and cost-effective ways to deliver follow-up care which maximises quality of life 
for prostate cancer survivors.  Given that men in this study have reported high levels of satisfaction 
with current, largely hospital-led, follow-up care, it is important secondary and primary care health 
professionals work together with patients to come up with cost-effective models that are acceptable 
to all.   
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Table 1. Patient demographics and disease characteristics 
Variable/characteristic (Total N = 315) Median Inter-quartile Range 
Patient age (years) (n = 293) 68 64-81 
Time since diagnosis (months) (n = 315) 17 14-25 
Marital Status n % 
Single 6 1.9 
Married/Cohabiting 275 89.0 
Widowed 12 3.9  
Divorced/Separated 9 2.9
Other 7 2.3 
Total 309*
Employment Status n % 
In paid work 107 34.6
Temporarily off sick 1 0.3 
Unemployed 3 1.0
Retired 189 61.2 
Long-term disability or ill health 4 1.3 
Full-time education, training or work experience 0 0.0 
Other 5 1.6 
Total 308* 
Ethnicity n % 
White British 292 94.8 
White - Other 11 3.6 
Black - other 1 0.3 
Chinese 1 0.3 
Other 3 1.0 
Total 308*
Educational Status n % 
O Level/GCSE 50 16.7
A Level 19 6.4
Clerical or commercial qualification 32 10.7
College or university degree 64 21.4
Postgraduate qualification 40 13.4 
None of these 94 31.4
Total 299* 
Co-morbidity n % 
Heart problems 35 11.1 
High Blood Pressure 118 37.5
Chronic obstructive pulmonary disease 8 2.5 
Asthma 22 7.0
Diabetes 29 9.2 
Arthritis 44 14.0
Osteoporosis 2 0.6 
Inflammatory Bowel Disease 3 1.0
Other 51 16.2 
At least one co-morbidity 205 65.1
No co-morbidities 110 34.9 
Previous treatment** n % 
Surgery 115 36.5 
Radiotherapy – external beam 125 39.7
Brachytherapy – implanted radioactive seeds 17 5.4 
Hormone 138 43.8
Active Surveillance 86 27.3 
Other 8 2.5
* Total excludes missing data** Some men had received more than one type of treatment 
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Table 2 Symptoms experienced in previous 4 weeks, by treatment type  
 
All 
N =315 
Surgery  
n = 115 
Radiotherapy 
n = 36 
Radiotherapy 
with adjuvant 
hormone 
therapy 
n= 81 
Primary 
hormone 
therapy 
n = 36 
Active 
surveillance 
n = 43 
 
P-value 
Urinary Function 
  
Incontinence        
Leaking >1 time/day 31/309 (10%) 23 (21%) 2 (6%) 3 (4%) 2 (6%) 1 (2%)
Frequent dribbling 14/310 (5%) 7 (6%) 1 (3%) 5 (6%) 1 (3%) 0 (0%)
Any pad use 33/301 (11%) 25 (22%) 1 (3%) 3 (4%) 2 (6%) 2 (5%)
Leaking problem* 23/287 (8%) 13 (12%) 2 (7%) 5 (7%) 0 (0%) 3 (8%)  
Overall Domain Score** 
(n = 268) 94 (73-100) 86 (67-100) 100 (79-100) 100 (78-100) 100 (86-100) 93.8 (86-100) 0.039 
Irritation/obstruction*        
Dysuria 2/276 (1%) 0 (0%) 0 (0%) 1 (1%) 1 (3%) 0 (0%)  
Haematuria 1/275 (0%) 0 (0%) 1 (3%) 0 (0%) 0 (0%) 0 (0%)
Weak stream 35/283 (12%) 8 (7%) 4 (15%) 10 (14%) 5 (16%) 8 (23%)
Frequency 50/293 (17%) 17 (15%) 7 (23%) 13 (17%) 5 (15%) 7 (19%)
Overall Domain Score** 
(n = 260) 94 (81-100) 94 (88-100) 88 (81-94) 88 (75-100) 88 (81-100) 88 (75-100)  
Overall Urinary Problem* 48/309 (16%) 16 (14%) 6 (17%) 13 (17%) 5 (14%) 7 (17%) 0.087 
Bowel function        
Urgency* 21/302 (7%) 3 (3%) 2 (6%) 12 (15%) 2 (6%) 1 (3%)
Frequency* 19/286 (7%) 4 (4%) 2 (7%) 12 (16%) 0 (0%) 0 (0%)
Incontinence* 9/287 (3%) 1 (1%) 2 (7%) 4 (5%) 1 (3%) 0 (0%)
Bloody stools* 8/283 (3%) 2 (2%) 1 (4%) 5 (7%) 0 (0%) 0 (0%)
Rectal pain* 9/287 (3%) 5 (5%) 0 (0%) 3 (4%) 0 (0%) 1 (3%)
Overall Domain Score** 
(n = 277) 100 (92-100) 100 (96-100) 92 (83-100) 94 (79-100) 100 (96-100) 100 (96-100) - 
Overall Bowel Problem* 16/311 (5%) 4 (3%) 1 (3%) 10 (13%) 0 (0%) 0 (0%)  
Sexual function        
Poor erections 233/289 (81%) 93 (83%) 22 (73%) 70 (93%) 29 (94%) 16 (43%)  
Orgasm difficulty 201/275 (73%) 70 (64%) 21 (72%) 64 (90%) 27 (100%) 17 (49%)  
Erections not firm*** 248/289 (86%) 97 (87%) 24 (80%) 71 (95%) 30 (97%) 23 (61%)  
Erections not 
reliable*** 222/274 (81%) 94 (87%) 23 (77%) 66 (96%) 27 (100%) 17 (47%)  
Poor sexual function 233/285 (82%) 90 (81%) 22 (73%) 70 (96%) 29 (100%) 19 (50%)  
Overall Domain Score** 
(n = 271) 17 (4-32) 16.7 (4-36) 13.8 (0-43) 12.5 (4-17) 16.7 (8-17) 57 (13-88) 0.000 
Overall Sexual Function* 115/289 (40%) 54 (47%) 12 (39%) 28 (38%) 9 (27%) 11 (30%)
Vitality/hormonal function*  
Hot flushes 60/295 (20%) 14 (13%) 7 (23%) 28 (37%) 9 (26%) 2 (5%)
Breast Tenderness 9/278 (3%) 3 (3%) 2 (8%) 4 (6%) 0 (0%) 0 (0%)
Depression 22/285 (8%) 8 (7%) 1 (4%) 8 (11%) 5 (16%) 0 (0%)
Lack of energy 63/297 (21%) 14 (13%) 6 (19%) 28 (36%) 10 (29%) 5 (13%)
Weight gain 41/287 (14%) 10 (9%) 4 (14%) 17 (23%) 6 (18%) 4 (12%)
Overall Domain Score** 
(n = 273) 90 (75-100) 95 (85-100) 95 (70-100) 75 (55-90) 78 (68-90) 95 (90-100) 0.000 
 
*Responses were dichotomised to only include moderate or big problems. **Domain scores out of 100, where 100=best 
possible score. Medians and interquartile ranges reported. ***Categorised as ‘erections not firm’ if respondents stated 
that their erections were not firm enough for intercourse. Categorised as ‘erections not reliable’ if respondent could not 
achieve erections more than half the time when desired. Due to heavily skewed data, p-values for domain scores were 
produced using a non-parametric test which compares medians across groups. 
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Table 3: Most common unmet needs (low/moderate/high) 
 
Not 
Applicable 
Need was 
satisfied Low need 
Moderate 
need High need 
N (%) N (%) N (%) N (%) N (%) 
Pain (n=308) 264 (86%) 20 (6%) 14 (5%) 5 (2%) 5 (2%) 
Lack of Energy (n=304) 207 (67%) 36 (12%) 30 (10%) 21 (7%) 10 (3%)
Feeling unwell a lot of the time (n=306) 259 (84%) 16 (5%) 21 (7%) 9 (3%) 1 (0%)
Work around the home (n=306) 250 (81%) 24 (8%) 21 (7%) 10 (3%) 1 (0%) 
Not being able to do the things you used to do (n=309) 225 (73%) 28 (9%) 26 (8%) 21 (7%) 9 (3%) 
Anxiety (n=306) 227 (74%) 26 (8%) 30 (10%) 16 (5%) 7 (2%)
Feeling down or depressed (n=309) 226 (73%) 22 (7%) 37 (12%) 16 (5%) 8 (3%) 
Feelings of sadness (n=307) 224 (73%) 27 (9%) 32 (10%) 18 (6%) 6 (2%) 
Fears about the cancer spreading (n=309) 152 (49%) 60 (19%) 60 (19%) 26 (8%) 11 (4%) 
Worry that the results of treatment are beyond your control 
(n=304) 187 (61%) 45 (15%) 42 (14%) 25 (8%) 5 (2%) 
Uncertainty about the future (n=306) 171 (56%) 37 (12%) 62 (20%) 30 (10%) 6 (2%)
Learning to feel in control of your situation (n=306) 194 (63%) 44 (14%) 52 (17%) 12 (4%) 4 (1%) 
Keeping a positive outlook (n=306) 212 (69%) 44 (14%) 37 (12%) 7 (2%) 6 (2%) 
Feelings about death and dying (n=307) 218 (71%) 36 (12%) 33 (11%) 12 (4%) 8 (3%)
Changes in sexual feelings (n=303) 169 (55%) 33 (11%) 46 (15%) 35 (11%) 20 (6%) 
Changes in your sexual relationships (n=303) 178 (58%) 34 (11%) 41 (13%) 30 (10%) 20 (6%) 
Concern about the worries of those close to you (n=304) 154 (50%) 54 (18%) 48 (16%) 28 (9%) 20 (6%) 
More choice about which cancer specialist you see (n=306) 245 (80%) 28 (9%) 21 (7%) 9 (3%) 3 (1%)
More choice about which hospital you attend (n=306) 252 (82%) 34 (11%) 12 (4%) 7 (2%) 1 (0%) 
Reassurance by medical staff that the way you feel is normal 
(n=307) 202 (66%) 58 (19%) 28 (9%) 10 (3%) 9 (3%) 
Hospital staff attending promptly to your physical needs (n=305) 225 (73%) 47 (15%) 13 (4%) 13 (4%) 7 (2%) 
Hospital staff acknowledging and showing sensitivity to your 
feelings and emotional needs (n=306) 199 (65%) 71 (23%) 17 (6%) 12 (4%) 7 (2%) 
Being given written information about the important aspects of 
your care (n=309) 190 (62%) 75 (24%) 24 (8%) 8 (3%) 12 (4%) 
Being given information (written, diagrams, drawings) about 
aspects of managing your illness and side-effects at home 
(n=310) 
194 (63%) 74 (24%) 18 (6%) 14 (5%) 10 (3%) 
Being given explanations of those tests for which you would like 
explanations (n=307) 180 (58%) 81 (26%) 22 (7%) 10 (3%) 14 (5%) 
Being adequately informed about the benefits and side-effects of 
treatments before you choose to have them (n=306) 175 (57%) 79 (26%) 22 (7%) 17 (6%) 13 (4%) 
Being informed about your test results as soon as feasible 
(n=311) 147 (48%) 96 (31%) 29 (9%) 21 (7%) 18 (6%) 
Being informed about cancer which is under control or 
diminishing (that is remission) (n=309) 179 (58%) 81 (26%) 21 (7%) 17 (6%) 11 (4%) 
Being informed about things you can do to help yourself get well 
(n=308) 185 (60%) 62 (20%) 31 (10%) 20 (6%) 10 (3%) 
Having access to professional counselling (eg, psychologist, 
social worker, counsellor, nurse specialist) if you, family or friends 
need it (n=310) 
229 (74%) 38 (12%) 19 (6%) 14 (5%) 10 (3%) 
Being given information about sexual relationships (n=308) 207 (67%) 35 (11%) 35 (11%) 15 (5%) 16 (5%) 
Being treated like a person not just another case (n=309) 191 (62%) 82 (27%) 14 (5%) 9 (3%) 13 (4%) 
Being treated in a hospital or clinic that is as physically pleasant 
as possible (n=310) 194 (63%) 88 (29%) 5 (2%) 13 (4%) 10 (3%) 
Having one member of hospital staff who you can talk to about all 
aspects of your condition, treatment or follow-up (n=309) 178 (58%) 78 (25%) 25 (8%) 16 (5%) 12 (4%) 
 
 
 
Table 4. Differences in mean EQ-5D-3L index score for those reporting moderate or large symptom 
problems 
 
 
No Moderate/Big 
Problem 
Moderate/Big 
Problem  
 Mean (SD) Mean (SD) P-value* 
Urine Function 0.868 (0.160) 0.773 (0.222) 0.001
Bowel Function 0.862 (0.166) 0.653 (0.195) 0.000 
Sexual Function 0.861 (0.176) 0.838 (0.170) 0.261 
*P-values were calculated using a 2-group independent samples t-test. A
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